Clinical Trials Logo

Clinical Trial Summary

This study will determine the frequency of Staphylococcus aureus carriage in household contacts of individuals with clinical infection due to this pathogen. It will also assess the frequency of transmission events over the following three months. Finally it will aim to identify predisposing characteristics both on a demographic/social level as well virulence characteristics of the identified strains.


Clinical Trial Description

This is a prospective cohort study based at Anuradhapura Teaching Hospital (Sri Lanka). Potential index study participants will have clinical infection caused by Staphylococcus aureus and will be identified from hospital microbiology laboratory records within 48 hours of admission. With consent, the investigators will approach up to 4 household members for participation in the carriage study. With their consent, household members will have swabs collected on 2 occasions 3 months apart. All hospitalised patients will receive standard-of-care treatment in accordance with local practice and national guidance. Clinical, demographic and social/lifestyle data will be collected from index patients and households by scheduled interview performed by local investigators. Bacterial isolates from the initial index patient infection, and those identified through household member screening will be assessed for antimicrobial susceptibility, virulence factor repertoire and analysed by whole genome sequencing. While infection with the cc5 MRSA clone has been described in several hospital and hospital-associated settings in South Asia a major unresolved issue is whether transmission and circulation of this clone is occurring in community settings. In this study the investigators will investigate and characterise the household circulation of Staphylococcus aureus strains, exploring differences in bacterial virulence characteristics and host susceptibility factors associated with increased risk of carriage. Understanding these factors and estimating the burden of disease which may be occurring in the community setting will allow more accurate assessment of the risk posed by cc5 PVL-MRSA to similar Low and Middle Income Countries (LMIC) settings and signal potential routes to mitigation through treatment optimisation and disease prevention including infection control or vaccination. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04884958
Study type Observational
Source University of Sheffield
Contact Thomas Darton
Phone +44 114 215 9530
Email t.darton@sheffield.ac.uk
Status Not yet recruiting
Phase
Start date May 2021
Completion date September 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05073926 - Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Completed NCT01212120 - The Foot in Your Nose Study: Links Between Nasal Staphylococcus Aureus Colonies and Diabetic Foot Lesion Infections N/A
Completed NCT00801879 - Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection Phase 4
Terminated NCT03638947 - Reducing Perioperative S. Aureus Transmission N/A
Recruiting NCT05331885 - A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 Phase 3
Recruiting NCT05094570 - Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP Phase 4
Not yet recruiting NCT05092464 - Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis N/A
Recruiting NCT05695196 - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant Phase 1
Enrolling by invitation NCT04666532 - S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
Active, not recruiting NCT02572791 - Staph Household Intervention for Eradication (SHINE) Phase 4
Recruiting NCT04274348 - Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum N/A
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed NCT01011335 - Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial Phase 1/Phase 2
Completed NCT03816956 - Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 Phase 3
Completed NCT01105767 - Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees N/A
Completed NCT00475930 - Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates N/A
Completed NCT00507247 - Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus Phase 2
Recruiting NCT03220386 - Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making N/A
Completed NCT03140423 - Mupirocin-Iodophor ICU Decolonization Swap Out Trial Phase 4
Not yet recruiting NCT03869593 - Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria